262 related articles for article (PubMed ID: 34597653)
1. Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis.
Wu X; Lu Y; Qin X
J Ethnopharmacol; 2022 Jan; 283():114690. PubMed ID: 34597653
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle arrest is an important mechanism of action of compound Kushen injection in the prevention of colorectal cancer.
Sun J; Li M; Lin T; Wang D; Chen J; Zhang Y; Mu Q; Su H; Wu N; Liu A; Yu Y; Liu Y; Wang S; Yu X; Guo J; Yu W
Sci Rep; 2022 Mar; 12(1):4384. PubMed ID: 35288618
[TBL] [Abstract][Full Text] [Related]
3. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
[TBL] [Abstract][Full Text] [Related]
4. A selective p53 activator and anticancer agent to improve colorectal cancer therapy.
Ramos H; Soares MIL; Silva J; Raimundo L; Calheiros J; Gomes C; Reis F; Monteiro FA; Nunes C; Reis S; Bosco B; Piazza S; Domingues L; Chlapek P; Vlcek P; Fabian P; Rajado AT; Carvalho ATP; Veselska R; Inga A; Pinho E Melo TMVD; Saraiva L
Cell Rep; 2021 Apr; 35(2):108982. PubMed ID: 33852837
[TBL] [Abstract][Full Text] [Related]
5. Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Compound Kushen Injection in Anti-Cancer Effect.
He R; Ou S; Chen S; Ding S
Med Sci Monit; 2020 Jan; 26():e918520. PubMed ID: 31892693
[TBL] [Abstract][Full Text] [Related]
6. Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/β-catenin pathway.
Xu W; Lin H; Zhang Y; Chen X; Hua B; Hou W; Qi X; Pei Y; Zhu X; Zhao Z; Yang L
J Exp Clin Cancer Res; 2011 Oct; 30(1):103. PubMed ID: 22032476
[TBL] [Abstract][Full Text] [Related]
7. Compound Kushen injection inhibits EMT of gastric cancer cells via the PI3K/AKT pathway.
Li L; Wang K; Liu Z; Lü Y; Wang C; Yi X; Guo J
World J Surg Oncol; 2022 May; 20(1):161. PubMed ID: 35590327
[TBL] [Abstract][Full Text] [Related]
8. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib.
Yang Y; Sun M; Yao W; Wang F; Li X; Wang W; Li J; Gao Z; Qiu L; You R; Yang C; Ba Q; Wang H
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179631
[TBL] [Abstract][Full Text] [Related]
9. Differences in p53 status significantly influence the cellular response and cell survival to 1,25-dihydroxyvitamin D3-metformin cotreatment in colorectal cancer cells.
Abu El Maaty MA; Strassburger W; Qaiser T; Dabiri Y; Wölfl S
Mol Carcinog; 2017 Nov; 56(11):2486-2498. PubMed ID: 28618116
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.
Bagnoli M; Balladore E; Luison E; Alberti P; Raspagliesi F; Marcomini B; Canevari S; Mezzanzanica D
Mol Cancer Ther; 2007 Feb; 6(2):762-72. PubMed ID: 17308072
[TBL] [Abstract][Full Text] [Related]
11. Elucidating the pharmacological effects of Compound Kushen injection on MYC-P15-CCND1 signaling pathway in nasopharyngeal carcinoma - An in vitro study.
Wu Z; Wu C; Shi J; Huang Z; Lu S; Tan Y; You R; Hai L; Huang J; Guo S; Gao Y; Jin Z; Tao X; You L; Wu J
J Ethnopharmacol; 2023 Oct; 315():116702. PubMed ID: 37257705
[TBL] [Abstract][Full Text] [Related]
12. Lipoic Acid Synergizes with Antineoplastic Drugs in Colorectal Cancer by Targeting p53 for Proteasomal Degradation.
Neitzel C; Seiwert N; Göder A; Diehl E; Weber C; Nagel G; Stroh S; Rasenberger B; Christmann M; Fahrer J
Cells; 2019 Jul; 8(8):. PubMed ID: 31366086
[TBL] [Abstract][Full Text] [Related]
13. Identification of candidate anti-cancer molecular mechanisms of Compound Kushen Injection using functional genomics.
Qu Z; Cui J; Harata-Lee Y; Aung TN; Feng Q; Raison JM; Kortschak RD; Adelson DL
Oncotarget; 2016 Oct; 7(40):66003-66019. PubMed ID: 27602759
[TBL] [Abstract][Full Text] [Related]
14. Cooperation of SRPK2, Numb and p53 in the malignant biology and chemosensitivity of colorectal cancer.
Wang G; Sheng W; Tang J; Li X; Zhou J; Dong M
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31898732
[TBL] [Abstract][Full Text] [Related]
15. Tanshinone I induces human colorectal cancer cell apoptosis: The potential roles of Aurora A-p53 and survivin-mediated signaling pathways.
Lu M; Wang C; Wang J
Int J Oncol; 2016 Aug; 49(2):603-10. PubMed ID: 27279458
[TBL] [Abstract][Full Text] [Related]
16. Restoration of the tumor-suppressor function to mutant p53 by Ganoderma lucidum polysaccharides in colorectal cancer cells.
Jiang D; Wang L; Zhao T; Zhang Z; Zhang R; Jin J; Cai Y; Wang F
Oncol Rep; 2017 Jan; 37(1):594-600. PubMed ID: 27878254
[TBL] [Abstract][Full Text] [Related]
17. Tenacissoside G synergistically potentiates inhibitory effects of 5-fluorouracil to human colorectal cancer.
Wang K; Liu W; Xu Q; Gu C; Hu D
Phytomedicine; 2021 Jun; 86():153553. PubMed ID: 33906076
[TBL] [Abstract][Full Text] [Related]
18. p53 dependence and apoptosis in response to FP treatment with p53-transfected colon cancer cell lines by use of thin layer collagen gel.
Matsuhashi N; Saio M; Matsuo A; Sugiyama Y; Saji S
Oncol Rep; 2004 Aug; 12(2):357-61. PubMed ID: 15254702
[TBL] [Abstract][Full Text] [Related]
19. A New Strategy for Identifying Mechanisms of Drug-drug Interaction Using Transcriptome Analysis: Compound Kushen Injection as a Proof of Principle.
Shen H; Qu Z; Harata-Lee Y; Cui J; Aung TN; Wang W; Kortschak RD; Adelson DL
Sci Rep; 2019 Nov; 9(1):15889. PubMed ID: 31685921
[TBL] [Abstract][Full Text] [Related]
20. Butyrate supplementation regulates expression of chromosome segregation 1‑like protein to reverse the genetic distortion caused by p53 mutations in colorectal cancer.
Chang CC; Kao WY; Liu CY; Su HH; Kan YA; Lin PY; Ku WC; Chang KW; Yang RN; Huang CJ
Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35417036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
